Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777249 | 1.00 | PRMT5 (0.44) | PRMT5WDR77GPR119PIK3CDHPGD | |
| SCHEMBL21767695 | 1.00 | PRMT5 (0.44) | PRMT5WDR77GPR119PIK3CDHPGD | |
| SCHEMBL5039027 | 0.92 | HPGD (0.46) | PRMT5WDR77GPR119HPGDRECQL | |
| SCHEMBL6132494 | 0.91 | GPR119 (0.47) | PRMT5WDR77GPR119HPGDRECQL | |
| SCHEMBL7685759 | 0.91 | GPR119 (0.47) | PRMT5WDR77GPR119HPGDRECQL | |
| SCHEMBL30750595 | 0.91 | GPR119 (0.47) | PRMT5WDR77GPR119HPGDRECQL | |
| SCHEMBL22907261 | 0.89 | NR1H2 (0.46) | PRMT5WDR77GPR119HPGDMEN1 | |
| SCHEMBL21997478 | 0.88 | HPGD (0.47) | PRMT5WDR77GPR119HPGDMAPT | |
| SCHEMBL28684525 | 0.86 | PRMT5 (0.46) | PRMT5WDR77GPR119PIK3CDHPGD | |
| SCHEMBL13107602 | 0.86 | PRMT5 (0.46) | PRMT5WDR77GPR119PIK3CDHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552786-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3843728-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHR¿DINGER, LLC | 2024-11-14 | — | — | US | disclosed |
| WO-2024173570-A1 | INHIBITING αvβ8 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4086254-A1 | INTEGRIN INHIBITORS | Morphic Therapeutic, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHRÖDINGER, LLC | 2020-12-10 | — | — | US | disclosed |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3617206-A1 | INTEGRIN INHIBITORS | Morphic Therapeutic, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | PRMT5 2149/4885WDR77 3706/4885GPR119 1070/4885 |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | ITGB6, ITGA6, GP6 | PRMT5 3274/4885WDR77 3009/4885GPR119 1240/4885 |
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PRMT5 2339/4885WDR77 3749/4885GPR119 1209/4885 |
| US-12552786-B2 | Inhibitors of αvβ6 integrin | ITGB6, ITGB1, ITGA6 | PRMT5 3064/4885WDR77 4602/4885GPR119 1650/4885 |
| US-20200071322-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PRMT5 2339/4885WDR77 3749/4885GPR119 1209/4885 |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PRMT5 2339/4885WDR77 3749/4885GPR119 1209/4885 |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PRMT5 2339/4885WDR77 3749/4885GPR119 1209/4885 |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PRMT5 2339/4885WDR77 3749/4885GPR119 1209/4885 |
| US-11021480-B2 | Inhibiting (α-V)(β-6) integrin | ITGB6, ITGA6, ITGAV | PRMT5 2149/4885WDR77 3706/4885GPR119 1070/4885 |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | PRMT5 2149/4885WDR77 3706/4885GPR119 1070/4885 |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PRMT5 2631/4885WDR77 4056/4885GPR119 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.